Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 5, 2025
uniQure to Announce First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial …
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
May 5, 2025
- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive data from the Company’s ongoing Phase 2a trial of lead …
Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook
GlobeNewswire
·
May 5, 2025
Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company …
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
GlobeNewswire
·
May 5, 2025
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence …
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
GlobeNewswire
·
May 5, 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial …
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewswire
·
May 5, 2025
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT …
Solésence Reports Record First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today …
Xenon to Report Q1 2025 Financial Results on May 12, 2025
GlobeNewswire
·
May 5, 2025
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for …
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 5, 2025
– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – …
DrEO Clinic Named Best Hair Transplant Clinic in Mexico for 2025, Leading the Way in Affordable Medical Tourism
GlobeNewswire
·
May 5, 2025
Mexico City, Mexico, May 05, 2025 (GLOBE NEWSWIRE) -- DrEO Clinic has been recognized as the best hair transplant clinic in Mexico for 2025, reinforcing its position at the forefront of hair restoration excellence. The announcement follows endorsements …
Robert Olsen Receives Individual Achievement Award from the Healthcare Financial Management Association
GlobeNewswire
·
May 5, 2025
NASHVILLE, Tenn., May 05, 2025 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) today presented Robert Olsen with the 2025 Frederick C. Morgan Individual Achievement Award, honoring career-long contributions to HFMA and to the …
Prostate Cancer Types Market Set for Robust Growth Through 2034, Driven by Advances in Targeted Therapies and Biomarker | DelveInsight
GlobeNewswire
·
May 5, 2025
New York, USA, May 05, 2025 (GLOBE NEWSWIRE) -- Prostate Cancer Types Market Set for Robust Growth Through 2034, Driven by Advances in Targeted Therapies and Biomarker | DelveInsight The prostate cancer market is expected to witness significant growth …
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
GlobeNewswire
·
May 5, 2025
ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH, "Voyager"), announced today a co- …
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
GlobeNewswire
·
May 5, 2025
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period. Oral presentation at DDW 2025 of clinical data from …
OSE Immunotherapeutics annonce que plus de 90% des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab
GlobeNewswire
·
May 5, 2025
OSE Immunotherapeutics annonce que plus de 90 % des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab Bonne tolérance de Lusvertikimab pendant les 24 semaines supplémentaires de traitement. …
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
GlobeNewswire
·
May 5, 2025
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell …
How individuals grasp an object may offer simpler diagnosis for autism spectrum disorder
GlobeNewswire
·
May 5, 2025
Toronto, May 05, 2025 (GLOBE NEWSWIRE) -- Getting a timely diagnosis of autism spectrum disorder is a major challenge, but new research out of York University shows that how young adults, and potentially children, grasp objects could offer a simpler way to …
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
GlobeNewswire
·
May 5, 2025
PRESS RELEASE AB SCIENCE TO PRESENT NEW DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS IN TWO PRESENTATIONS AT THE 2025 ENCALS ANNUAL MEETING MASITINIB REDUCES SERUM NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS, SUGGESTING THAT IT HAS …
AB Science présentera lors de la réunion annuelle de l’ENCALS en 2025 de nouvelles données issues du programme de développement clinique du masitinib dans la SLA
GlobeNewswire
·
May 5, 2025
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTERA LORS DE LA RÉUNION ANNUELLE DE L'ENCALS EN 2025 DE NOUVELLES DONNÉES ISSUES DU PROGRAMME DE DEVELOPPEMENT CLINIQUE DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE LE MASITINIB RÉDUIT LA CONCENTRATION SERIQUE …
Arialief Reviews (CRITICAL INVESTIGATION) What Doctors Say About Arialief's Safety And Complaints!
GlobeNewswire
·
May 5, 2025
ALBANY, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Arialief is a thoughtfully designed natural nerve pain relief supplement that can address the root issues behind various symptoms associated with neuropathy. It is backed up by solid research and combines …